BBR Partners LLC Has $210,000 Holdings in Stryker Co. (NYSE:SYK)

BBR Partners LLC decreased its position in Stryker Co. (NYSE:SYK) by 36.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 583 shares of the medical technology company’s stock after selling 338 shares during the period. BBR Partners LLC’s holdings in Stryker were worth $210,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of SYK. Principal Financial Group Inc. grew its position in shares of Stryker by 6.2% during the 3rd quarter. Principal Financial Group Inc. now owns 398,422 shares of the medical technology company’s stock worth $143,934,000 after buying an additional 23,329 shares during the period. Kornitzer Capital Management Inc. KS grew its holdings in Stryker by 1.9% in the third quarter. Kornitzer Capital Management Inc. KS now owns 8,084 shares of the medical technology company’s stock worth $2,920,000 after purchasing an additional 152 shares during the period. Hara Capital LLC bought a new stake in Stryker in the third quarter valued at $42,000. Portside Wealth Group LLC bought a new stake in Stryker in the third quarter valued at $215,000. Finally, Tandem Investment Advisors Inc. raised its holdings in shares of Stryker by 8.2% during the third quarter. Tandem Investment Advisors Inc. now owns 266,041 shares of the medical technology company’s stock valued at $96,110,000 after purchasing an additional 20,199 shares during the period. Institutional investors own 77.09% of the company’s stock.

Insider Activity at Stryker

In other news, Director Allan C. Golston sold 2,458 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now owns 14,895 shares of the company’s stock, valued at $5,705,827.65. This represents a 14.16 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. The trade was a 5.24 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by company insiders.

Stryker Trading Down 0.8 %

Shares of Stryker stock opened at $379.28 on Friday. The firm has a market cap of $144.73 billion, a PE ratio of 48.88, a P/E/G ratio of 2.93 and a beta of 0.96. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The stock has a fifty day moving average price of $382.45 and a 200-day moving average price of $372.78.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the prior year, the firm earned $3.46 earnings per share. Equities research analysts anticipate that Stryker Co. will post 13.47 EPS for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a $0.84 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.89%. Stryker’s dividend payout ratio (DPR) is presently 43.30%.

Wall Street Analysts Forecast Growth

SYK has been the subject of a number of research analyst reports. Argus set a $450.00 target price on Stryker in a research report on Monday, February 3rd. The Goldman Sachs Group boosted their price objective on Stryker from $384.00 to $427.00 and gave the company a “neutral” rating in a report on Thursday, January 30th. Truist Financial lifted their price target on shares of Stryker from $409.00 to $413.00 and gave the company a “hold” rating in a research report on Thursday, January 30th. JMP Securities restated a “market perform” rating on shares of Stryker in a report on Tuesday, February 18th. Finally, Morgan Stanley upgraded shares of Stryker from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $370.00 to $445.00 in a report on Monday, December 2nd. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat.com, Stryker presently has a consensus rating of “Moderate Buy” and a consensus price target of $422.15.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.